Medical Market Report

Global Oncology Biosimilars Market By Type (G-CSF, Hematopoietic Agents, and Monoclonal Antibodies), By Application (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 137005
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    The report on Oncology Biosimilars Market offers in-depth analysis of market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global oncology biosimilars market is segmented on the basis of Type, Application, and geography.

    The Worldwide market for Oncology Biosimilars Market is expected to grow at a CAGR of roughly x.x% over the next nine years, and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.

    Oncology Biosimilars Market Scope:

    By type, the market is segmented into G-CSF, Hematopoietic Agents, and Monoclonal Antibodies. By Application, the market is divided into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Celltrion Inc., Pfizer Inc., Biocon, BIOCAD, Apotex Inc., Dr. Reddy’s, Dr. Reddy’s, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd.

    Key Market Segments

    Type

    G-CSF
    Hematopoietic Agents
    Monoclonal Antibodies

    Application

    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

    Key Market Players included in the report:

    Celltrion Inc.
    Pfizer Inc.
    Biocon
    BIOCAD
    Apotex Inc.
    Dr. Reddy’s
    Dr. Reddy’s
    Intas Pharmaceuticals Ltd.
    STADA Arzneimittel AG
    Teva Pharmaceutical Industries Ltd

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Oncology Biosimilars Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Oncology Biosimilars Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Oncology Biosimilars Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Oncology Biosimilars Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Oncology Biosimilars Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Oncology Biosimilars Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Oncology Biosimilars sub-markets, depending on key regions (various vital states).
    To analyze Oncology Biosimilars Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Oncology Biosimilars Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2014 to 2019, and also prediction to 2028.
    Primary worldwide Oncology Biosimilars Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Oncology Biosimilars Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global Oncology Biosimilars Market Overview
    

    3.1. Oncology Biosimilars Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy4. Global Oncology Biosimilars Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Oncology Biosimilars Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. G-CSF
    

      4.4. Hematopoietic Agents
    

      4.5. Monoclonal Antibodies5. Global Oncology Biosimilars Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Oncology Biosimilars Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Retail Pharmacies
    

      5.4. Hospital Pharmacies
    

      5.5. Online Pharmacies6. Global Oncology Biosimilars Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Oncology Biosimilars Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Oncology Biosimilars Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Oncology Biosimilars Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Oncology Biosimilars Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Oncology Biosimilars Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global Oncology Biosimilars Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Celltrion Inc.
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4. Pfizer Inc.
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Biocon
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6. BIOCAD
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Apotex Inc.
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8. Dr. Reddy’s
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Dr. Reddy’s
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10. Intas Pharmaceuticals Ltd.
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. STADA Arzneimittel AG
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12. Teva Pharmaceutical Industries Ltd
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.